For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the poly(adp-ribose) polymerase (parp) inhibitors industry, and what is its expected CAGR?
The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to increasing cancer incidence, increasing genetic testing, increasing success in clinical trials, growing insurance coverage, and growth in cancer research.
The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising production and supply of drugs, the growing prevalence of BRCA-mutated cancers, the rising prevalence of breast cancer, the growing use of monoclonal antibodies, and the rising healthcare expenditure. Major trends in the forecast period include advancements in biomarker research, combination therapies, integration of artificial intelligence in drug development, advancements in biomarker-driven therapy, and development of next-generation PARP inhibitors.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
What external factors are influencing the poly(adp-ribose) polymerase (parp) inhibitors market’s growth momentum?
The rising prevalence of breast cancer is expected to propel the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market going forward. Breast cancer refers to a disease in which cells in the breast grow uncontrollably, forming a malignant tumor that can spread to other parts of the body. The rising prevalence of breast cancer is attributed to factors such as aging populations, lifestyle changes, genetic predisposition, hormonal imbalances, obesity, alcohol consumption, and increasing exposure to environmental risk factors. PARP inhibitors help breast cancer patients by blocking the PARP enzyme’s ability to repair DNA damage in cancer cells, leading to cell death, particularly in tumors with BRCA1 or BRCA2 mutations. For instance, in January 2025, according to the National Breast Cancer Foundation, a US-based organization, one in every eight women in the United States will be diagnosed with breast cancer during her lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. Therefore, the rising prevalence of breast cancer is driving the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
What are the major market segments driving the growth of the poly(adp-ribose) polymerase (parp) inhibitors industry?
The poly(ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –
1) By Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types
2) By Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers, HRD-Positive Cancers, Maintenance Therapy
2) By Rucaparib: Ovarian Cancer, Prostate Cancer, Pancreatic Cancer
3) By Niraparib: First-Line Treatment, Recurrent Cancer Treatment, Late-Stage Cancer
4) By Talazoparib: Breast Cancer, Germline BRCA-Mutated Tumors, Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors, Investigational Therapies, Novel Combinations
View The Full Market Report:
What are the key trends shaping the poly(adp-ribose) polymerase (parp) inhibitors market in the forecast period?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are focusing on developing advanced cancer treatments, such as anticancer medicines, to target specific genetic mutations prevalent in certain cancers. Anticancer medicines are drugs used to treat cancer by inhibiting the growth of cancer cells, preventing their spread, or destroying them. These medicines work through various mechanisms, including interfering with cell division, blocking specific proteins essential for tumor growth, or stimulating the immune system to fight cancer. For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched IBYRA, a generic version of the PARP inhibitor olaparib, in India. The drug provides an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers. It significantly reduces treatment costs compared to the innovator drug.
Who are the key market players contributing to the growth of the poly(adp-ribose) polymerase (parp) inhibitors industry?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Which regions are leading the growth of the poly(adp-ribose) polymerase (parp) inhibitors market globally?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102
Need Customized Data On Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
